Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma

The MajesTEC-3 trial of 587 relapsed multiple myeloma patients showed that a two-drug immunotherapy combination of teclistamab and daratumumab produced durable remissions, with over 83% of treated participants progression-free at three years and very rare recurrences after year one. The results prompted an FDA priority review and approval on March 5, underlining a potential paradigm shift away from traditional myeloma drugs and creating upside for stakeholders exposed to these therapies and the multiple myeloma treatment market.

Analysis

Market structure: The FDA-prioritized approval of the teclistamab + daratumumab combo creates immediate winners among large-cap drugmakers that own those assets (JNJ) and platform players with BCMA-directed bispecific/CAR-T pipelines (e.g., AMGN, REGN, GILD indirectly). Incumbents that rely on proteasome inhibitors or IMiDs (BMY/Celgene franchises, TAK’s Velcade) risk volume and pricing erosion over 2–5 years as payers and clinicians shift to durable immunotherapy-based regimens. Manufacturing capacity for bispecific antibodies becomes a choke point, creating short-term pricing power for suppliers of biologics CMO services and specialty distributors.

Risk assessment: Tail risks include post-marketing safety signals (immune toxicity) and payer refusals or restrictive step-therapy that could curb uptake; either could wipe out >40–60% of short-term revenue upside for sponsors. Time horizons: days–weeks see limited market moves; 3–9 months is critical for reimbursement and real-world uptake; 12–36 months decides frontline displacement. Hidden dependencies include CMS reimbursement decisions, hospital outpatient infusion throughput, and single-source biologics supply chains.

Trade implications: Tactical plays include concentration in sponsors/CMOs that scale bispecifics (establish 2–3% long in JNJ, add 0.5–1% in AMGN/REGN), paired with trimming 1–2% positions in BMY and TAK. Options: implement 12–18 month call spreads on JNJ sized to 0.5–1% portfolio risk to capture upside while limiting premium; consider buying short-dated protection (60–90 day puts) sized 0.5% until payer clarity. Entry: initiate within 2–6 weeks; exit/trim on +20–30% move or upon negative CMS decision within 90 days.

Contrarian angles: Consensus underestimates payer resistance and manufacturing limits; adoption could be slower than headlines imply, hurting near-term revenue while rewarding operators who control CMO capacity. Conversely, the market may underprice knock-on demand for biologics manufacturing and diagnostics (MRD testing) — mid-cap CMOs and diagnostics firms could outperform. Watch CMS coverage decisions in 30–60 days and real-world safety/uplift data at 6–9 months as decisive re-pricing events.

Key Decisions for Investors

• Establish a 2–3% long position in Johnson & Johnson (JNJ) within 2–6 weeks to capture revenue upside from the teclistamab + daratumumab combo; size with a 10% stop-loss and hedge with 0.5% notional of 12–18 month OTM protective puts to limit regulatory/safety risk.
• Implement a relative-value pair trade: long JNJ (1.5–2%) and short Bristol-Myers Squibb (BMY) (0.75–1%) targeting a 20–30% relative outperformance over 12–24 months as immunotherapy displaces IMiD-based maintenance; cut the short if BMY outperforms JNJ by >10% in 60 days.
• Buy a 12–18 month JNJ call spread sized to 0.5–1% portfolio risk (buy 10–20% OTM call, sell 30–40% OTM call) to capture upside with defined cost; roll or take profits on a >25% intrinsic move or after positive frontline trial readouts in 9–18 months.
• Trim 1–2% gross exposure to Takeda (TAK) and BMY over the next 3 months and redeploy proceeds: 0.5–1% into IBB (broad biotech ETF) for optionality on other bispecific/CAR-T winners and 0.5–1% into a CMO/biologics manufacturer with scalable capacity (select after 30–60 day supply-chain diligence).
• Monitor three specific catalysts and act: (1) CMS / private payer coverage decision within 30–60 days — add to longs on favorable coverage, (2) real-world safety/uptake metrics at 3–9 months — trim longs if adverse signals >5% grade ≥3 immune events, (3) Phase 3 frontline trial readouts in 9–18 months — double down if efficacy mirrors MajesTEC-3 (PFS >80% at 3 years).